文献速递外周动脉疾病

主髂动脉闭塞性疾病行腋股动脉旁路术后通畅率改善

Improved patency after axillofemoral bypass for aortoiliac occlusive disease.
PubMed 文献 · J Vasc Surg · 2018-08-09

该研究报告了1991年2月至2016年6月共161例腋股动脉旁路术(85例腋双股、76例腋单股)的15年经验,5年总体通畅率83.7%,腋双股81.8%与腋单股85.5%间无显著差异;作者认为采用现代方案和技术,腋股旁路可作为血管腔内治疗失败或不适合长期成功患者的可接受的有效首选干预。

要点

  • 161例腋股旁路术(85例腋双股、76例腋单股),5年总体通畅率83.7%。
  • 腋双股5年通畅率81.8% vs 腋单股85.5%,差异无统计学意义。
  • 5年生存率55%,30天内死亡仅3例(均为急性主动脉闭塞手术)。

核心结论

  • 作者认为,采用现代方案和技术行腋双股及腋单股旁路术,对于血管腔内治疗失败或不太可能获得长期成功的患者,可作为可接受的有效首选干预。
  • 作者认为,由于腋单股与腋双股通畅率相似,腋双股应保留用于双侧指征。

研究设计与样本

  • 单中心回顾性研究,纳入1991年2月至2016年6月共161例腋股动脉旁路术(85例腋双股、76例腋单股),91例男性、70例女性,中位年龄72.6岁(平均73岁,范围41-94岁)。
  • 所有病例均使用环加固8 mm膨体聚四氟乙烯(ePTFE)移植物;腋双股旁路的股-股交叉肢预先构建。
  • 术中给予肝素,并用鱼精蛋白逆转。
  • 主要通畅丧失定义为移植血管部分或全部血栓形成;5年主要通畅率采用Kaplan-Meier分析计算。

主要发现

  • 治疗指征为静息痛49.6%、缺血性病变26%、跛行22.3%、既往血运重建失败9.3%、感染3.7%、夹层动脉瘤1.2%。
  • 选择腋股而非股股旁路的原因包括:主动脉条件差44.1%、高风险19.2%、既往重建失败12.4%、高龄8.7%、感染4.3%、腹部条件差4.3%、主动脉夹层0.6%、病态肥胖0.6%。
  • 随访期间63例死亡,其中17例在术后第1年内死亡;仅3例在术后30天内死亡(均为治疗急性主动脉闭塞的手术)。
  • 5年生存率为55%。
  • 5年通畅率:所有手术83.7%,腋双股81.8%,腋单股85.5%;腋双股与腋单股之间差异无统计学意义。

关键数值与推荐

  • 5年主要通畅率:所有手术83.7%,腋双股81.8%,腋单股85.5%(腋双股与腋单股差异无统计学意义)。
  • 5年生存率55%;30天内死亡3例,均发生于因急性主动脉闭塞手术的患者。

临床怎么用

  • 作者认为,腋双股和腋单股旁路术采用现代方案和技术,对于血管腔内治疗失败或不太可能获得长期成功的患者,可作为可接受的有效首选干预。
  • 作者认为,该手术操作简单且死亡率和并发症率低,适合开放主动脉经验有限的外科医生开展。
  • 作者认为,由于腋单股与腋双股通畅率相似,腋双股应保留用于双侧指征。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Axillofemoral bypasses (AxFBs) have been used since 1962 to treat aortoiliac disease. In the past, reported patency rates (37%-76%) for these extra-anatomic grafts have been inferior to those for anatomic aortic grafting. Reported low survival rates after AxFB (40%-50%) have confirmed that these procedures have been used primarily in patients at high risk for complications from aortofemoral bypass. However, modern medical and anesthesia management, preoperative scanning, donor artery preparation, postoperative graft surveillance, and graft technology may improve outcomes after AxFB, possibly supporting expansion of its use. We therefore report our last 15-year experience with AxFB. METHODS: Ring-reinforced, 8-mm expanded polytetrafluoroethylene grafts were used in all cases. The cross-femoral limb of axillobifemoral bypass (AxBFB) grafts was preconstructed. Heparin was administered intraoperatively, with protamine reversal. Loss of primary patency was defined as graft thrombosis of part or all of the inserted graft. Five-year primary patency rates were calculated by Kaplan-Meier analysis. RESULTS: Between February 1991 and June 2016, a total of 161 grafts were inserted (85 AxBFBs and 76 axillounifemoral bypasses [AxUFBs]) in 91 male and 70 female patients (median age, 72.6 years; mean age, 73 years; range, 41-94 years). Indications for treatment were rest pain (49.6%), ischemic lesions (26%), claudication (22.3%), failed prior revascularization (9.3%), infection (3.7%), and dissecting aneurysm (1.2%). Reasons for performing AxFB rather than aortofemoral bypass were hostile aorta (44.1%), high risk (19.2%), prior failed reconstruction (12.4%), advanced age (8.7%), infection (4.3%), hostile abdomen (4.3%), aortic dissection (0.6%), and morbid obesity (0.6%). During follow up, 63 patients died, 17 within the first year; but only 3 patients died within 30 days of surgery (performed to treat an acute aortic occlusion). The 5-year survival rate was 55%. Five-year patency rates were 83.7% for all procedures, 81.8% for AxBFB, and 85.5% for AxUFB; the difference between AxBFB and AxUFB was not significant. CONCLUSIONS: Our data indicate that AxBFB and AxUFB performed with the use of modern protocols and technology may render them an acceptable valid primary intervention in patients in whom endovascular treatment has failed or is unlikely to offer long-term success. The simplicity of performing these grafts and their low mortality and morbidity lend their application to surgeons with limited open aortic experience. Because AxUFB and AxBFB have similar patency rates, AxBFB should be reserved for bilateral indications.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Samson RH, Showalter DP, Lepore MR, et al. Improved patency after axillofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 2018. PMID: 29691098. doi:10.1016/j.jvs.2018.01.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。